undamentalytics Newsletter
Sign in

Urogen Pharma Ltd. (URGN) stock

Add to watchlist

Add holding +

NASDAQ: URGN Nasdaq Biotechnology Next results ~November 4, 2026

C+ Fundamentals grade

Urogen Pharma Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$40

Valuation models combined (3)

Base case. Range ~$32–$46. Weighted average of 3 models (growth cash-flow model, forward price-to-earnings vs peers, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Urogen Pharma Ltd. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 15 sales by directors and officers, last 12 monthsInsider trades
  • Funds99 adding, 75 cuttingOf 40 active managers that changed their stake, 24 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Urogen Pharma files

Where Urogen Pharma stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $189m, up 100.3% on a year earlier, faster than the 52.9% growth a quarter earlier. That growth ranks 8 of 49 among the biotechnology companies we cover. Free-cash-flow margin rose to -84.3% from -131.1% a year earlier. Operating margin widened to -35.3% from -131.1%. The diluted share count is up 4.7% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 1 of our 4 financial-health checks. Our revenue-to-maturity cash-flow model value is $5.07 a share, against a share price of $34.21.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Urogen Pharma Ltd.'s trailing-twelve-month revenue grew 100.3% year on year, with a free-cash-flow margin of -84.3%. Where it stands out: change in growth rate of +47.3pp ranks 28 of 172 biotechnology companies we cover. Where it lags: long-term debt as % of assets of 74.7% ranks 75 of 78 biotechnology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 100.3% (+47.3pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 100.3% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 47.3 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 95.8 points on a year ago.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 73.2% over 90 days.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -35.3%: costs exceed revenue.
  • Burning cash. Free cash flow was -84.3% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 4.7% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 63% and a beta of 1.2 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 74.7% ranks 75 of 78 biotechnology companies we cover (median 20.6%).

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.28 against an average estimate of -$0.27: missed by 5.7%
Revenue
$72m, up 199.2% on a year earlier
Share reaction
+14.2% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 4, 2026; average EPS estimate $0.09

Urogen Pharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+5.0%
  • 1 week+0.9%
  • 1 month-17.0%
  • This year+46.7%
  • 1 year+67.9%
  • 5 years+82.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$189M
Operating margin
-35.3%
Net margin
-51.7%
EPS (TTM, diluted)
$-1.97

Growth

Revenue growth
+100.3%
Change in growth rate
+47.3 pts
Share count change
+4.7%

Cash

Free cash flow (TTM)
-$159M
FCF margin
-84.3%
Stock pay % of revenue
8.5%

Earnings

Last results
August 5, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Insider trade
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Urogen Pharma Ltd. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Urogen Pharma Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.11 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$46 ~$23–$67 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$32 ~$29–$61 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$33 ~$34–$130 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$40 ~$32–$46 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Urogen Pharma Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201720182019202020212022202320242025Now
Share price$37.21$43.06$33.37$18.02$9.51$8.87$15.00$10.65$23.42$34.36
Market value$362m$678m$685m$392m$213m$202m$433m$457m$1.1bn$1.7bn
+ Net debt (− = net cash)−$37m−$101m−$50m−$53m−$44m$42m$4m−$50m$14m$121m
Enterprise value$325m$577m$635m$340m$168m$244m$436m$406m$1.1bn$1.8bn
Multiples
Price / sales 44.3xn/mn/m33.3x4.4x3.1x5.2x5.1x10.3x9.0x
Price / earnings ——————————
Price / free cash flow ——————————
EV / EBITDA ——————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

25 /100

Weak moat

How hard Urogen Pharma's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -27.8% of total assets over 6 years.

  • Pricing power 20 / 20

    Gross margin has been a median 89.5%, moving by 1.0 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -131.1%; its worst year was -473.5%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -124.6% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 122.9% over five years; stock-based pay has been a median 13.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (30 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $90m and EPS of $0.09 (range −$0.07 to $0.19) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.24 +92% $321m +192%
Next $2.59 +1165% $523m +63%

Next year's EPS estimate has moved +73.2% in 90 days, across 7 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −65.6% on 90 days ago. In the last 30 days, 5 analysts raised Urogen Pharma Ltd.'s forecast and 0 cut it.

Consensus EPS forecast Urogen Pharma Ltd., last 90 days
−$1.00 $0.00 $1.00 $2.00 $3.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.70 Current fiscal year, 60 days ago: −$0.24 Current fiscal year, 30 days ago: −$0.24 Current fiscal year, 7 days ago: −$0.24 Current fiscal year, Now: −$0.24 −$0.24 Next fiscal year, 90 days ago: $1.49 Next fiscal year, 60 days ago: $2.79 Next fiscal year, 30 days ago: $2.79 Next fiscal year, 7 days ago: $2.79 Next fiscal year, Now: $2.59 $2.59

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.70$1.49
60 days ago −$0.24$2.79
30 days ago −$0.24$2.79
7 days ago −$0.24$2.79
Now −$0.24$2.59

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.27 −$0.28 −5.7%
Mar 2026 −$0.48 −$0.47 +2.6%
Dec 2025 −$0.51 −$0.53 −3.6%
Sept 2025 −$0.68 −$0.69 −1.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

8 analysts, Oct 2026
Buy788%
Hold113%
Sell00%

Monthly trend

  1. Oct 20261618
  2. Sep 20261618
  3. Aug 20261618
  4. Jul 20261618

Counts of recommendations published by analysts covering Urogen Pharma Ltd., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.7%
of tradable shares
Days to cover
5.87
at average volume
Short interest, 1 month
−10%
to October 15, 2026
Held by institutions
98%
of shares
Held by insiders
3.5%
of shares
Employees
300
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +67.9%

$20.47 on October 31, 2025 to $34.36

ThenNowEffect
Revenue (last 12 months) $94m $189m +100.3%
P/S multiple 10.3x 9.0x −12.2%
Share count 47m 49m −4.5%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
URGN−47%−7%+69%−29%+120%+47%
Industry peers (median)−35%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
URGN42%42%50%33%75%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
URGN−67%−47%−52%−46%−68%−35%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since May 4, 2017: 94% from May 18, 2018 to May 27, 2025. Getting back needed a 1562% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$17.00 – $50.29
From 52-week high
−31.7%
vs 50-day average
−14.5%
vs 200-day average
+9.5%
Volatility (1 year)
63%
Beta vs S&P 500
1.20

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±9.0%
After a week
8 up, 4 down
typical move ±12.7%
After a month
6 up, 6 down
typical move ±12.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +14.2% −0.4% +22.7% +12.4%
May 6, 2026 +11.6% +1.1% +29.8% +12.7%
March 2, 2026 −13.3% −0.8% −8.2% −17.1%
November 6, 2025 +20.4% −1.0% +23.9% +19.5%
August 7, 2025 −11.3% +0.7% +0.3% +7.0%
May 12, 2025 −2.3% +4.0% −23.2% −29.7%
March 10, 2025 +10.2% −3.5% +16.6% −1.6%
November 6, 2024 −0.9% +3.3% −0.4% +0.7%
August 13, 2024 +2.9% +2.0% +3.4% −10.1%
May 13, 2024 +1.8% +0.5% +1.3% −0.2%
March 14, 2024 −17.2% −0.9% −14.5% −13.6%
November 14, 2023 −1.5% +2.2% +7.7% +29.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Urogen Pharma Ltd. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Urogen Pharma Ltd.
$50M $100M $150M $200M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $77.3M Revenue (TTM), FY23 Q4: $82.7M Revenue (TTM), FY24 Q1: $84.3M Revenue (TTM), FY24 Q2: $85M Revenue (TTM), FY24 Q3: $89.4M Revenue (TTM), FY24 Q4: $90.4M Revenue (TTM), FY25 Q1: $91.9M Revenue (TTM), FY25 Q2: $94.2M Revenue (TTM), FY25 Q3: $96.5M Revenue (TTM), FY25 Q4: $109.8M Revenue (TTM), FY26 Q1: $140.5M Revenue (TTM), FY26 Q2: $188.7M $188.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $77.3M
FY23 Q4 $82.7M
FY24 Q1 $84.3M
FY24 Q2 $85M
FY24 Q3 $89.4M
FY24 Q4 $90.4M
FY25 Q1 $91.9M
FY25 Q2 $94.2M
FY25 Q3 $96.5M
FY25 Q4 $109.8M
FY26 Q1 $140.5M
FY26 Q2 $188.7M
Revenue growth, TTM YoY Urogen Pharma Ltd.
0% 50% 100% 150% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 23.8% Revenue growth, TTM YoY, FY23 Q4: 28.5% Revenue growth, TTM YoY, FY24 Q1: 24.0% Revenue growth, TTM YoY, FY24 Q2: 17.2% Revenue growth, TTM YoY, FY24 Q3: 15.6% Revenue growth, TTM YoY, FY24 Q4: 9.3% Revenue growth, TTM YoY, FY25 Q1: 9.0% Revenue growth, TTM YoY, FY25 Q2: 10.9% Revenue growth, TTM YoY, FY25 Q3: 8.0% Revenue growth, TTM YoY, FY25 Q4: 21.4% Revenue growth, TTM YoY, FY26 Q1: 52.9% Revenue growth, TTM YoY, FY26 Q2: 100.3% 100.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 23.8%
FY23 Q4 28.5%
FY24 Q1 24.0%
FY24 Q2 17.2%
FY24 Q3 15.6%
FY24 Q4 9.3%
FY25 Q1 9.0%
FY25 Q2 10.9%
FY25 Q3 8.0%
FY25 Q4 21.4%
FY26 Q1 52.9%
FY26 Q2 100.3%
Operating margin (TTM) Urogen Pharma Ltd.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -92.2% Operating margin (TTM), FY23 Q4: -79.2% Operating margin (TTM), FY24 Q1: -82.1% Operating margin (TTM), FY24 Q2: -93.7% Operating margin (TTM), FY24 Q3: -93.7% Operating margin (TTM), FY24 Q4: -107.1% Operating margin (TTM), FY25 Q1: -117.5% Operating margin (TTM), FY25 Q2: -131.1% Operating margin (TTM), FY25 Q3: -138.2% Operating margin (TTM), FY25 Q4: -113.7% Operating margin (TTM), FY26 Q1: -77.0% Operating margin (TTM), FY26 Q2: -35.3% -35.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -92.2%
FY23 Q4 -79.2%
FY24 Q1 -82.1%
FY24 Q2 -93.7%
FY24 Q3 -93.7%
FY24 Q4 -107.1%
FY25 Q1 -117.5%
FY25 Q2 -131.1%
FY25 Q3 -138.2%
FY25 Q4 -113.7%
FY26 Q1 -77.0%
FY26 Q2 -35.3%
FCF margin (TTM) Urogen Pharma Ltd.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -110.4% FCF margin (TTM), FY23 Q4: -92.6% FCF margin (TTM), FY24 Q1: -97.8% FCF margin (TTM), FY24 Q2: -101.2% FCF margin (TTM), FY24 Q3: -107.9% FCF margin (TTM), FY24 Q4: -107.4% FCF margin (TTM), FY25 Q1: -116.9% FCF margin (TTM), FY25 Q2: -131.1% FCF margin (TTM), FY25 Q3: -143.1% FCF margin (TTM), FY25 Q4: -148.2% FCF margin (TTM), FY26 Q1: -118.2% FCF margin (TTM), FY26 Q2: -84.3% -84.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -110.4%
FY23 Q4 -92.6%
FY24 Q1 -97.8%
FY24 Q2 -101.2%
FY24 Q3 -107.9%
FY24 Q4 -107.4%
FY25 Q1 -116.9%
FY25 Q2 -131.1%
FY25 Q3 -143.1%
FY25 Q4 -148.2%
FY26 Q1 -118.2%
FY26 Q2 -84.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 18 8 1 0 12 48 64 83 90 110 189
Gross profit 18 8 −1 0 11 43 57 73 82 97 171
EBITDA 1 −20 −77 −109 −126 −91 −78 −65 −96 −125 −66
Operating income 1 −20 −77 −109 −127 −92 −79 −66 −97 −125 −67
Net income −2 −20 −76 −105 −128 −111 −110 −102 −127 −153 −98
Diluted EPS −$0.48 −$2.14 −$4.80 −$5.12 −$5.90 −$4.96 — — — — −$1.97
Growth (year on year)
Revenue — −53.5% −86.2% −98.4% +>999% +307.2% +34.0% +28.5% +9.3% +21.4% +100.3%
EBITDA — <−999% — — — — — — — — —
Operating income — <−999% — — — — — — — — —
Margins
Gross margin 99.8% 92.6% −59.8% 100.0% 91.4% 89.3% 88.1% 88.7% 90.2% 88.7% 90.8%
EBITDA margin 5.7% −242.1% <−999% <−999% <−999% −190.4% −121.4% −78.3% −106.7% −113.5% −35.1%
Operating margin 4.6% −244.5% <−999% <−999% <−999% −192.1% −122.8% −79.2% −107.1% −113.7% −35.3%
Net margin −11.1% −245.2% <−999% <−999% <−999% −230.7% −170.6% −123.6% −140.4% −139.8% −51.7%
Free-cash-flow margin 19.9% −120.6% <−999% <−999% −907.7% −178.3% −136.4% −92.6% −107.4% −148.2% −84.3%
Cash flow
Cash from operations 4 −10 −37 −71 −106 −85 −88 −76 −97 −162 −159
Capital spending 1 0 1 0 1 1 0 0 0 0 0
Free cash flow 3 −10 −38 −71 −107 −86 −88 −77 −97 −163 −159
Stock-based pay 2 6 31 30 28 23 11 9 13 12 16
Free cash flow after stock pay 2 −16 −69 −101 −135 −109 −98 −86 −110 −175 −175
Balance sheet
Cash 21 37 101 50 53 44 55 95 172 111 79
Total debt 0 0 0 0 0 0 98 99 122 125 200
Net debt (negative = net cash) −21 −37 −101 −50 −53 −44 42 4 −50 14 121
Diluted shares 9m 10m 16m 21m 22m 22m 23m 29m 43m 48m 49m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 4 checks passed · June 30, 2026
What it owns · $253m
Short-term assets $235mLonger-term assets $17m
What it owes, and who funded it · $385m
Short-term liabilities $62mLonger-term liabilities $323mShareholders' equity $-132m
  • Short-term assets cover short-term liabilities $235m of assets due within a year against $62m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $235m short-term assets against $323m of longer-dated liabilities.
  • More cash than debt $79m of cash against $189m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$159m of operating cash flow against $189m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Urogen Pharma Ltd.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+4.7%
year over year
R&D spending
32.5%
of revenue
Sales & admin spending
93.7%
of revenue
Days sales outstanding
172 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated URGN ABUS VALN NUVB IBRX AKBA Median
Revenue, last 12 months $189m $182m $197m $170m $166m $219m $56m
Revenue growth, last 12 months 100.3% >999% 7.6% >999% 192.9% 7.5% 12.6%
Revenue growth, 3-year average 37.6% 97.6% — — 554.3% 2.9% 13.7%
Revenue growth, latest quarter 199.2% −90.6% — 555.6% 93.9% −21.4% 10.2%
Gross margin 90.8% — 38.7% 54.3% 99.3% 79.6% 82.9%
Operating margin −35.3% 82.0% −47.0% −81.0% −151.9% −6.9% −189.4%
Operating margin, 3-year average −86.7% −377.3% — <−999% <−999% −8.9% −363.5%
Net margin −51.7% 84.2% −66.0% −88.2% −598.6% −13.5% −169.8%
Cash from operations / revenue −84.2% −13.6% −30.3% −70.9% −169.6% 19.0% −168.0%
Free-cash-flow margin −84.3% −13.6% −32.8% −72.2% −173.8% 18.4% −162.4%
Free-cash-flow margin, 3-year average −105.5% −376.7% — <−999% <−999% −1.7% −310.0%
Stock pay / revenue 8.5% 3.0% 5.5% 20.9% 20.7% 6.1% 20.0%
Change in share count 4.7% 1.9% 15.4% 9.5% 26.1% 11.8% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 100.3% 12.6% 40 of 172
Change in growth rate Growth +47.3pp -0.1pp 28 of 172
Gross margin Profitability 90.8% 82.4% 20 of 75
Operating margin Profitability -35.3% -189.4% 58 of 175
Net margin Profitability -51.7% -157.3% 64 of 180
Free-cash-flow margin Cash generation -84.3% -145.4% 80 of 176
Stock pay as % of revenue Cash generation 8.5% 19.2% 54 of 179
Long-term debt as % of assets Balance sheet 74.7% 20.6% 75 of 78
Change in share count Balance sheet 4.7% 7.9% 63 of 156
Days sales outstanding Balance sheet 172 days 75 days 94 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Jelmyto $94M 85.6% ▲ 4.0%
Zusduri $15.8M 14.4% —

From Urogen Pharma Ltd.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.6B
Institutions reporting
188
Shares held vs prior quarter
▼ 8.7%
Positions opened / closed
39 / 21

Top buyers and sellers, Q2 2026: 99 institutions bought and 75 sold ; the biggest buyer was Point72 Asset Management, L.P (+1.5M shares) and the biggest seller Toronto Dominion Bank (−2.6M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RTW Investments, LP $167M 4.5M 10.7% 0.0%
Blackrock, Inc. $118M 3.2M 7.6% ▲ 12.5%
Morgan Stanley $94.8M 2.6M 6.1% ▲ 0.6%
Kynam Capital Management, LP $89.6M 2.4M 5.7% ▲ 8.3%
Jefferies Financial Group Inc. $80.9M 2.2M 5.2% 0.0%
SG Americas Securities, LLC $75.5M 2.1M 4.8% ▲ 23.8%
American Century Companies Inc $62M 1.7M 4.0% ▲ 2.9%
Acorn Capital Advisors, LLC $61.6M 1.7M 3.9% 0.0%
Point72 Asset Management, L.P. $56.1M 1.5M 3.6% New
Frontier Capital Management Co LLC $55.5M 1.5M 3.6% ▲ 14.8%
Opaleye Management Inc. $53M 1.4M 3.4% ▲ 0.7%
Silverarc Capital Management, LLC $47.9M 1.3M 3.1% ▼ 13.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Urogen Pharma Ltd.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $4.8M 15 trades by 3 insiders · 27% under pre-set plans
Net ▼ $4.8M net selling
Insider Date Trade Shares Price Value
Degnan Chris Chief Financial Officer October 8, 2026 Sell 2,202 $36.69 $80,791
Smith Jason Drew General Counsel September 8, 2026 Sell 1,519 $42.54 $64,618
Schoenberg Mark Chief Medical Officer September 8, 2026 Sell 871 $42.92 $37,383
Schoenberg Mark Chief Medical Officer August 20, 2026 Sell 60,677 $47.05 $2.9M
Schoenberg Mark Chief Medical Officer July 9, 2026 Sell pre-set plan 10,000 $40.00 $400,000
Schoenberg Mark Chief Medical Officer June 22, 2026 Sell pre-set plan 10,000 $35.01 $350,100
Schoenberg Mark Chief Medical Officer June 8, 2026 Sell 5,222 $27.30 $142,561
Schoenberg Mark Chief Medical Officer May 8, 2026 Sell pre-set plan 10,000 $30.00 $300,000
Schoenberg Mark Chief Medical Officer February 3, 2026 Sell 1,844 $19.69 $36,308
Schoenberg Mark Chief Medical Officer February 3, 2026 Sell 3,686 $19.69 $72,577
Schoenberg Mark Chief Medical Officer February 3, 2026 Sell 1,843 $19.69 $36,289
Smith Jason Drew General Counsel February 3, 2026 Sell 2,654 $19.69 $52,257

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • March 2, 2026
  • November 6, 2025
  • August 7, 2025
  • May 12, 2025

Recent SEC filings

Data status

When each part of this page on Urogen Pharma Ltd. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Urogen Pharma Ltd. in brief

What does Urogen Pharma Ltd. do?
Urogen Pharma Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Urogen Pharma Ltd.'s stock ticker?
Urogen Pharma Ltd. trades under the ticker URGN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Urogen Pharma Ltd.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Urogen Pharma Ltd. reported revenue of $189M, 100.3% higher than a year earlier, according to its SEC filings.
What is Urogen Pharma Ltd.'s free cash flow?
Urogen Pharma Ltd.'s free-cash-flow margin is -84.3% of revenue over the trailing twelve months, ranking 80 of the 176 biotechnology companies we cover.
Who are Urogen Pharma Ltd.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RTW Investments, LP, Blackrock, Inc. and Morgan Stanley. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Urogen Pharma Ltd.'s market cap?
On November 2, 2026, Urogen Pharma Ltd.'s market capitalisation was about $1.7B and net debt of $121M. Market figures come from third-party market data and may be delayed.
Who are Urogen Pharma Ltd.'s competitors?
In our Biotechnology peer group, the companies closest to Urogen Pharma Ltd. are Arbutus Biopharma Corp, Valneva SE, Nuvation Bio Inc., Immunitybio, Inc. and Akebia Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Urogen Pharma Ltd.'s.
Are insiders buying or selling Urogen Pharma Ltd. stock?
Over the last 12 months, Urogen Pharma Ltd.'s directors and officers reported 0 open-market purchases and 15 sales on Form 4. The insider trading page charts every trade.
When is Urogen Pharma Ltd.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Urogen Pharma Ltd. announces its own schedule.